期刊文献+

磷酸瑞格列汀结合缬沙坦在健康志愿者体内的药代动力学分析 被引量:2

Pharmacokinetic analysis of repagliptin phosphate combined with valsartan in healthy volunteers
下载PDF
导出
摘要 目的分析健康人口服磷酸瑞格列汀和缬沙坦后体内的药代动力学变化。方法随机选取医院体检的健康志愿者20例进行研究(男女比例1∶1),口服磷酸瑞格列汀片和缬沙坦胶囊,通过液相色谱串联质谱测定受试者血浆中的瑞格列汀、瑞格列汀酸和缬沙坦的药物浓度,同时对药代动力学参数的变化进行分析。结果单独服用磷酸瑞格列汀或与缬沙坦结合服用后,其主要产物磷酸瑞格列汀和磷酸瑞格列汀酸的药代动力学的趋势基本保持一致;此外,与单独服用磷酸瑞格列汀相比,磷酸瑞格列汀与缬沙坦结合服用后,其在Cmax、AUClast、AUCINFobs方面差异无统计学意义(P>0.05);同时,磷酸瑞格列汀和磷酸瑞格列汀酸的Cmax、AUC的90%置信区间介于80%~125%范围内的等效区间内;受试者在服用瑞格列汀和缬沙坦24 h后,其尿液中瑞格列汀和缬沙坦的累积排泄率未发生显著改变。结论健康人群同时服用磷酸瑞格列汀和缬沙坦后,在其体内未发现相互干扰的药代动力学参数变化。 Objective To analyze the pharmacokinetics of healthy people after oral administration of repagliptin phosphate and valsartan.Methods Twenty healthy volunteers from the hospital were randomly selected for study(1∶1 male to female ratio).They were orally administered with repagliptin phosphate tablets and valsartan capsules.The concentration of repagliptin,repagliptin and valsartan in the plasma of the subject was determined by liquid chromatography-tandem mass spectrometry,and the changes in pharmacokinetic parameters were analyzed.Results After taking repagliptin phosphate alone or in combination with valsartan,the main pharmacokinetics of repagliptin phosphate and repagliptin phosphate were basically the same;In addition,compared with rigagliptin phosphate alone,there was no significant difference in Cmax,AUClast,AUCINFobs after taking rigagliptin phosphate in combination with valsartan(P>0.05).After taking rigagliptin phosphate alone or in combination with valsartan,the main products of repagliptin phosphate and repagliptin phosphate,had a consistent trend in pharmacokinetics;Meanwhile,the 90%confidence intervals of Cmax and AUC of repagliptin phosphate and repagliptin phosphate were in the equivalent range of 80%to 125%;The cumulative excretion rates of repagliptin and valsartan in the urine did not change significantly after 24 h of rigagliptin and valsartan.Conclusion After taking repagliptin phosphate and valsartan in healthy people,no changes in the pharmacokinetic parameters of mutual interference were found in the body.
作者 罗海 LUO Hai(Pharmacy,China 19th Metallurgical Group Co.,Ltd.Staff Hospital,Sichuan Province,Panzhihua 617000,China)
出处 《临床合理用药杂志》 2019年第22期18-20,共3页 Chinese Journal of Clinical Rational Drug Use
关键词 磷酸瑞格列汀 缬沙坦 健康志愿者 药代动力学 Repagliptin phosphate Valsartan Healthy volunteers Pharmacokinetics
  • 相关文献

参考文献14

二级参考文献125

  • 1周月宏,王秋月.CTGF在糖尿病肾病发病机制中的作用及意义[J].国际内分泌代谢杂志,2006,26(4):273-276. 被引量:20
  • 2胡群力,梁群,蔡其云.缬沙坦干预非杓型高血压者恢复杓型血压昼夜节律后对血醛固酮水平的影响[J].中国临床药理学与治疗学,2007,12(1):116-118. 被引量:5
  • 3赵林双,廖玉华,向光大,王敏,侯洁,乐岭,孙慧玲,周子华.缬沙坦治疗抗血管紧张素Ⅱ1型受体自身抗体阳性的高血压合并糖尿病肾病的疗效[J].中华高血压杂志,2007,15(6):469-472. 被引量:23
  • 4ROTHER KI. Diabetes treatment--bridging the divide [ J]. N Engl J Med, 2007, 356(15) : 1499 - 1501.
  • 5International Diabetes Federation [ EB/OL ]. ( 2013 ). http :/! www. idf. org/sites/default/files/attachments/ IDF-BRIDGES- World-Guide-2013. pdf 2013.
  • 6GENEVA W. Global status report on noncommunicable diseases 2010 Description of the global burden of NCDs, their risk factors and determinants[EB/OL]. (2011). http://www, who. int/ nmh/publications/ncd_report2010/en/.
  • 7HWANG CK, HAN PV, ZABETIAN A, et al. Rural diabetes prevalence quintuples over twenty-five years in low- and middle- income countries: a systematic review and meta-analysis[ J]. Di- abetes Res Clin Pract, 2012, 96(3 ) : 271 -285.
  • 8DEACON CF, HOLST JJ. Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes [ J ]. lnt J Biochem Cell Biol, 2006, 38 (5 - 6) : 831 - 844.
  • 9YABE D, SEINO Y. Two incretin hormones GLP-I and GIP: comparison of their actions in insulin secretion and !3 cell preser- vation[J]. Prog Biophys Mol Biol, 2011, 107(2) : 248 -256.
  • 10DRUCKER DJ, NAUCK MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase.-4 inhibitors in type 2 diabetes[ J]. Lancet, 368 (9548) : 1696 - 1705.

共引文献206

同被引文献13

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部